Champions Oncology, Inc. (CSBR): Price and Financial Metrics

Champions Oncology, Inc. (CSBR): $7.75

0.18 (+2.38%)

POWR Rating

Component Grades













Add CSBR to Watchlist
Sign Up

Industry: Biotech



in industry

CSBR Stock Summary

  • Champions Oncology Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 92.3% of US listed stocks.
  • CSBR's current price/earnings ratio is 255.63, which is higher than 97.62% of US stocks with positive earnings.
  • Over the past twelve months, CSBR has reported earnings growth of -146.26%, putting it ahead of merely 13.04% of US stocks in our set.
  • Stocks that are quantitatively similar to CSBR, based on their financial statements, market capitalization, and price volatility, are CYBE, SPNS, SIGA, LQDT, and SCYX.
  • Visit CSBR's SEC page to see the company's official filings. To visit the company's web site, go to

CSBR Valuation Summary

  • CSBR's EV/EBIT ratio is 308.7; this is 953.58% higher than that of the median Healthcare stock.
  • Over the past 177 months, CSBR's EV/EBIT ratio has gone up 659.1.
  • Over the past 177 months, CSBR's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for CSBR.

Stock Date P/S P/B P/E EV/EBIT
CSBR 2021-08-31 3.2 17.5 359.1 308.7
CSBR 2021-08-30 3.3 18.0 370.2 317.8
CSBR 2021-08-27 3.3 18.0 369.3 317.2
CSBR 2021-08-26 3.4 18.5 379.8 325.9
CSBR 2021-08-25 3.4 18.5 379.8 325.9
CSBR 2021-08-24 3.3 18.4 376.8 323.3

CSBR Growth Metrics

    Its year over year revenue growth rate is now at 27.76%.
  • Its 2 year cash and equivalents growth rate is now at 729.22%.
  • Its 3 year revenue growth rate is now at 142.06%.
CSBR's revenue has moved up $29,275,000 over the prior 52 months.

The table below shows CSBR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 46.796 3.721 0.438
2021-09-30 44.415 -0.401 0.391
2021-06-30 42.746 -0.75 0.115
2021-03-31 41.04 -1.681 0.362
2020-12-31 39.224 2.844 -1.231
2020-09-30 37.424 2.988 -1.564

CSBR Price Target

For more insight on analysts targets of CSBR, see our CSBR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.67 Average Broker Recommendation 1.5 (Moderate Buy)

CSBR Stock Price Chart Interactive Chart >

Price chart for CSBR

CSBR Price/Volume Stats

Current price $7.75 52-week high $11.25
Prev. close $7.57 52-week low $6.81
Day low $7.57 Volume 9,400
Day high $7.75 Avg. volume 5,723
50-day MA $7.58 Dividend yield N/A
200-day MA $8.51 Market Cap 104.80M

Champions Oncology, Inc. (CSBR) Company Bio

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, the company provides POS products, including TumorGraft implants and drug panels, which utilizes TumorGraft technology to test the response of a patient's tumor to multiple oncology drugs or drug combinations. It markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

CSBR Latest News Stream

Event/Time News Detail
Loading, please wait...

CSBR Latest Social Stream

Loading social stream, please wait...

View Full CSBR Social Stream

Latest CSBR News From Around the Web

Below are the latest news stories about Champions Oncology Inc that investors may wish to consider to help them evaluate CSBR as an investment opportunity.

Champions Oncology-Fannin team up to develop therapeutics for tumors

Champions Oncology <> is collaborating with Fannin Innovation Studio to develop next generation therapeutics drug conjugates for tumors.The partnership will combine novel

Seeking Alpha | January 20, 2022

Champions Oncology Announces a Partnership with Fannin Innovation to Jointly Develop Therapeutic Raptamer Drug Conjugates

HACKENSACK, NJ / ACCESSWIRE / January 20, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced today a therapeutic co-development partnership with Fannin Innovation Studio.

Yahoo | January 20, 2022

Champions Oncology Announces a Partnership with Alloy Therapeutics to Develop Therapeutic Monoclonal Antibodies for Use in ADC Programs

HACKENSACK, NJ / ACCESSWIRE / January 4, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced today a therapeutic development partnership with Alloy Therapeutics.

Yahoo | January 4, 2022

Champions Oncology's (NASDAQ:CSBR) investors will be pleased with their impressive 149% return over the last five years

It hasn't been the best quarter for Champions Oncology, Inc. ( NASDAQ:CSBR ) shareholders, since the share price has...

Yahoo | January 4, 2022

Champions Oncology Inc (NASDAQ:CSBR) is debt free

Champions Oncology Inc (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, stock rose 3.23% (As The post Champions Oncology Inc (NASDAQ:CSBR) is debt free appeared first on FXDailyReport.Com .

FXDailyReport | December 14, 2021

Read More 'CSBR' Stories Here

CSBR Price Returns

1-mo 6.31%
3-mo -8.82%
6-mo -1.90%
1-year -18.76%
3-year -0.77%
5-year 173.85%
YTD -7.30%
2021 -22.52%
2020 29.53%
2019 6.66%
2018 101.29%
2017 53.36%

Continue Researching CSBR

Want to see what other sources are saying about Champions Oncology Inc's financials and stock price? Try the links below:

Champions Oncology Inc (CSBR) Stock Price | Nasdaq
Champions Oncology Inc (CSBR) Stock Quote, History and News - Yahoo Finance
Champions Oncology Inc (CSBR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5542 seconds.